Merrimack does not need to pay royalties to PharmaEngine for future sales of the drug in the US.Eyeing the potential of MM386 to treat multiple cancers, PharmaEngine estimated that potential sales of MM386 in Europe and Asia except Taiwan could reach US$500 million a year, PharmaEngine said.